LEGN 📈 Legend Biotech - Overview

Legend Biotech Corporation is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative cell therapies, primarily for the treatment of various types of cancer. Through its subsidiaries, the company operates in the United States, China, and internationally, leveraging its expertise in cell therapy to address significant unmet medical needs. Its product pipeline includes a range of autologous CAR-T cell therapies, which are designed to target specific cancer cells, thereby minimizing harm to healthy cells.

The company's lead product candidate, LCAR-B38M, is a chimeric antigen receptor (CAR) T-cell therapy intended for the treatment of multiple myeloma, a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. In addition to LCAR-B38M, Legend Biotech has a diverse portfolio of earlier-stage CAR-T product candidates that target a broad spectrum of cancers, including non-Hodgkin's lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. This comprehensive approach underscores the company's commitment to exploring the full potential of cell therapy in oncology.

Legend Biotech has established strategic partnerships to accelerate the development and commercialization of its product candidates. Notably, the company has a collaboration and license agreement with Janssen Biotech, Inc., a leading pharmaceutical company, for the development and commercialization of ciltacabtagene autoleucel, a CAR-T cell therapy. This partnership highlights the company's ability to collaborate with major industry players to advance its pipeline and bring innovative treatments to patients. Founded in 2014 and headquartered in Somerset, New Jersey, Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation, further enhancing its capabilities and resources in the biotechnology sector.

As a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol LEGN, Legend Biotech Corporation provides investors with the opportunity to participate in the growth and development of a pioneering biopharmaceutical company. With its strong focus on innovation, strategic partnerships, and commitment to improving patient outcomes, Legend Biotech is well-positioned to make a significant impact in the field of cell therapy and beyond. The company's common stock is classified under the GICS Sub Industry: Biotechnology, and its ISIN is US52490G1022, facilitating investment and tracking by institutional and individual investors alike.